Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An International Multi-center Phase 2 Study to Evaluate the Safety and Efficacy of Sequential Melphalan Hydrochloride for Injection for Use With the Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable Hepatocellular Carcinoma

Next Previous
Trial Profile

An International Multi-center Phase 2 Study to Evaluate the Safety and Efficacy of Sequential Melphalan Hydrochloride for Injection for Use With the Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable Hepatocellular Carcinoma

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 21 Dec 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Melphalan (Primary) ; Sorafenib
  • Indications Cholangiocarcinoma; Liver cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Delcath Systems

Most Recent Events

  • 14 Dec 2017 Status changed from recruiting to withdrawn prior to enrolment.
  • 14 Apr 2015 New source identified and integrated (ClinicalTrials.gov record: NCT02406508)
  • 07 Apr 2015 According to a Delcath Systems media release, Montefiore Medical Center in the Bronx, New York has joined the U.S Phase 2 HCC study and is now open for patient enrollment. The Company now has two centers participating in the U.S.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top